Show simple item record

dc.contributor.authorSpiess, K
dc.contributor.authorJeppesen, MG
dc.contributor.authorMalmgaard-Clausen, M
dc.contributor.authorKrzywkowski, K
dc.contributor.authorDulal, K
dc.contributor.authorCheng, T
dc.contributor.authorHjortø, GM
dc.contributor.authorLarsen, O
dc.contributor.authorBurg, JS
dc.contributor.authorJarvis, MA
dc.contributor.authorGarcia, KC
dc.contributor.authorZhu, H
dc.contributor.authorKledal, TN
dc.contributor.authorRosenkilde, MM
dc.date.accessioned2023-11-02T15:30:21Z
dc.date.available2023-11-02T15:30:21Z
dc.date.issued2015-07-07
dc.identifier.issn0027-8424
dc.identifier.issn1091-6490
dc.identifier.urihttps://pearl.plymouth.ac.uk/handle/10026.1/21559
dc.description.abstract

<jats:title>Significance</jats:title> <jats:p>All drugs currently used for the clinical treatment of human cytomegalovirus (HCMV) infection are associated with considerable adverse side effects and with the development of drug resistance that results in therapy failure. Here we describe a novel, rationally designed fusion toxin protein (FTP)-based strategy to target HCMV on the basis of its virally expressed G protein-coupled receptor (US28) and cognate chemokine ligand. Viral G protein-coupled receptors are expressed by a number of other clinically important viruses. We suggest that FTP-based molecules targeting virally expressed 7TM receptors may represent a new class of drugs amenable for development against complex viral pathogens.</jats:p>

dc.format.extent8427-8432
dc.format.mediumPrint-Electronic
dc.languageen
dc.publisherProceedings of the National Academy of Sciences
dc.subjectHCMV
dc.subject7TM GPCR
dc.subjectprotein engineering
dc.subjectantiviral drug
dc.subjectchemokine
dc.titleRationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/26080445
plymouth.issue27
plymouth.volume112
plymouth.publisher-urlhttp://dx.doi.org/10.1073/pnas.1509392112
plymouth.publication-statusPublished
plymouth.journalProceedings of the National Academy of Sciences
dc.identifier.doi10.1073/pnas.1509392112
plymouth.organisational-group|Plymouth
plymouth.organisational-group|Plymouth|Research Groups
plymouth.organisational-group|Plymouth|Faculty of Health
plymouth.organisational-group|Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group|Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED)|CBR
plymouth.organisational-group|Plymouth|REF 2021 Researchers by UoA
plymouth.organisational-group|Plymouth|Users by role
plymouth.organisational-group|Plymouth|Users by role|Academics
plymouth.organisational-group|Plymouth|REF 2021 Researchers by UoA|UoA01 Clinical Medicine
plymouth.organisational-group|Plymouth|Faculty of Health|School of Biomedical Sciences
dc.publisher.placeUnited States
dc.date.updated2023-11-02T15:30:20Z
dc.identifier.eissn1091-6490
dc.rights.embargoperiodforever
rioxxterms.versionofrecord10.1073/pnas.1509392112


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV